-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OSSM-007 in Graft Versus Host Disease (GVHD)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. OSSM-007 in Graft Versus Host Disease (GVHD) Drug Details: OSSM-007Â is under investigation for the prophylaxis...
-
Product Insights
Fistula – Drugs In Development, 2023
Global Markets Direct’s, ‘Fistula - Drugs In Development, 2023’, provides an overview of the Fistula pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fistula, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MICRO BONE MARROW TRANSPLANTS in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MICRO BONE MARROW TRANSPLANTS in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MICRO BONE MARROW TRANSPLANTS...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MICRO BONE MARROW TRANSPLANTS in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MICRO BONE MARROW TRANSPLANTS in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MICRO BONE MARROW TRANSPLANTS...
-
Product Insights
Graft Versus Host Disease (GVHD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Graft Versus Host Disease (GVHD) - Drugs In Development, 2023’, provides an overview of the Graft Versus Host Disease (GVHD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Bone Marrow Transplant Rejection – Drugs In Development, 2023
Global Markets Direct’s, ‘Bone Marrow Transplant Rejection - Drugs In Development, 2023’, provides an overview of the Bone Marrow Transplant Rejection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OSSM-001 in Fistula
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OSSM-001 in Fistula report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.OSSM-001 in FistulaDrug Details:OSSM-001 is under development for the treatment of ileal anal Anastomosis, ileal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AB-1015 in Peritoneal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AB-1015 in Peritoneal Cancer Drug Details:AB-1015 is under development for the treatment of ovarian cancer, fallopian...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GFH-009 in Peripheral T-Cell Lymphomas (PTCL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GFH-009 in Peripheral T-Cell Lymphomas (PTCL) Drug Details: GFH-009 is under development for the treatment...